As shown in Supplementary Figure 5C, patients in PLK1-high group had poorer prognosis compared to those in PLK1-low group both in MGMT promoter methylated and no-methylated glioma patients in CGGA-325, CGGA-693, and TCGA datasets. Here, MGMT is linked to central nervous system cancer.